A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment
Marc L Hyer1, Michael A Milhollen1, Jeff Ciavarri1
1Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
Abstract:
The ubiquitin-proteasome system (UPS) comprises a network of enzymes that is responsible for maintaining cellular protein homeostasis. The therapeutic potential of this pathway has been validated by the clinical successes of a number of UPS modulators, including proteasome inhibitors and immunomodulatory imide drugs (IMiDs). Here we identified TAK-243 (formerly known as MLN7243) as a potent, mechanism-based small-molecule inhibitor of the ubiquitin activating enzyme (UAE), the primary mammalian E1 enzyme that regulates the ubiquitin conjugation cascade. TAK-243 treatment caused depletion of cellular ubiquitin conjugates, resulting in disruption of signaling events, induction of proteotoxic stress, and impairment of cell cycle progression and DNA damage repair pathways. TAK-243 treatment caused death of cancer cells and, in primary human xenograft studies, demonstrated antitumor activity at tolerated doses. Due to its specificity and potency, TAK-243 allows for interrogation of ubiquitin biology and for assessment of UAE inhibition as a new approach for cancer treatment.
Insights
TAK-243 is a novel small-molecule inhibitor targeting the ubiquitin activating enzyme (UAE) in the ubiquitin-proteasome system. This drug depletes ubiquitin conjugates, induces cancer cell death, and shows antitumor activity, offering a new therapeutic strategy.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- The ubiquitin-proteasome system (UPS) is crucial for cellular protein homeostasis.
- Existing UPS modulators like proteasome inhibitors and IMiDs show therapeutic success.
- Targeting the ubiquitin conjugation cascade presents a novel therapeutic avenue.
Purpose of the Study:
- To identify and characterize TAK-243, a potent inhibitor of the ubiquitin activating enzyme (UAE).
- To investigate the effects of TAK-243 on cellular processes and its potential as an anticancer agent.
Main Methods:
- Mechanism-based inhibition of UAE by TAK-243.
- Assessment of cellular ubiquitin conjugate levels.
- Evaluation of signaling events, proteotoxic stress, cell cycle, and DNA damage repair.
- In vivo studies using human xenografts.
Main Results:
- TAK-243 treatment led to depletion of cellular ubiquitin conjugates.
- Disruption of signaling pathways, induction of proteotoxic stress, and impaired cell cycle/DNA repair.
- TAK-243 induced cancer cell death and demonstrated antitumor activity in xenograft models at tolerated doses.
Conclusions:
- TAK-243 is a specific and potent UAE inhibitor.
- UAE inhibition is a viable strategy for cancer treatment.
- TAK-243 serves as a valuable tool for studying ubiquitin biology and developing new cancer therapies.
Related Concept Videos
02:34Enzymes
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:13Enzymes and Activation Energy
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
02:56Treatment Resistant Cancers
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...